LINC00152 promotes proliferation in hepatocellular carcinoma by targeting EpCAM via the mTOR signaling pathway.
LINC00152 promotes proliferation in hepatocellular carcinoma by targeting EpCAM via the mTOR signaling pathway.
复制标题
DOI：
10.18632/oncotarget.5970
复制
发表时间：
2015-12-15
期刊：
影响因子：
--
通讯作者：
Sun B
中科院分区：
文献类型：
--
作者：
Ji J;Tang J;Deng L;Xie Y;Jiang R;Li G;Sun B
肝细胞癌是全球第六大常见恶性肿瘤，也是全球第三大癌症相关死亡原因。LINC00152是一种重要的长非编码RNA(LncRNA)，参与了胃癌的发生发展，但其具体作用机制尚不清楚。在此，基于LINC00152在肝细胞癌组织中的表达水平升高，我们发现LINC00152在体外可以促进细胞增殖，在体内可以促进肿瘤的生长。此外，GAL4-λN/boxB报告系统证实，LINC00152通过顺式调控与EPCAM启动子结合，激活雷帕霉素途径的机制靶点。因此，LINC00152可能通过激活mTOR信号通路参与肝细胞癌的发生发展，有望成为临床诊断的新指标。
Hepatocellular carcinoma (HCC) is well known as the sixth most common malignant tumor and the third leading cause of cancer-related deaths globally. LINC00152 was documented as an important long non-coding RNA (lncRNA) involved in the pathogenesis of gastric cancer; however, the detailed mechanism of action of LINC00152 remains unknown. Here, based on the increased level of LINC00152 in HCC tissues, we found that LINC00152 could promote cell proliferation in vitro and tumor growth in vivo. Furthermore, microarray-based analysis indicated that LINC00152 could activate the mechanistic target of rapamycin(mTOR) pathway by binding to the promoter of EpCAM through a cis-regulation, as confirmed by Gal4-λN/BoxB reporter system. Thus, LINC00152 might be involved in the oncogenesis of HCC by activating the mTOR signaling pathway and might be a novel index for clinical diagnosis in the future.